regulatory
confidence high
sentiment positive
materiality 0.60
Alaunos regains Nasdaq compliance after reporting $3.66M equity in Q2 2025
Alaunos Therapeutics, Inc.
- Nasdaq notified Alaunos of compliance on August 19, 2025, following prior stockholders' equity deficiency.
- Company had reported $2.06M equity in 2024 10-K, below $2.5M minimum for continued listing.
- Q2 2025 10-Q showed $3.66M equity, meeting Nasdaq's requirement; compliance plan submitted earlier.
- Matter closed; no immediate delisting risk.